| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Impairment of long-lived assets (note 4) | - | 0 |
| Net loss from continuing operations | -41 | -91 |
| Depreciation and amortization | 287 | 191 |
| Write-off of patents | 119 | 88 |
| Share-based compensation | 24 | 24 |
| Other | 587 | 370 |
| Other assets | -1,401 | -872 |
| Prepaid and other current assets | 188 | 192 |
| Accounts payable | 5 | 92 |
| Accrued expenses and other current liabilities | 509 | 84 |
| Lease liabilities | -752 | -445 |
| Other non-current liabilities | 128 | 87 |
| Total adjustments | 2,120 | 1,171 |
| Net cash provided by continuing operating activities | 2,079 | 1,080 |
| Net cash used in operating activities | -23 | -70 |
| Net increase in cash | 2,056 | 1,010 |
| Cash and cash equivalents at beginning of period | 5,059 | - |
| Cash and cash equivalents at end of period | 7,115 | - |
TherapeuticsMD, Inc. (TXMD)
TherapeuticsMD, Inc. (TXMD)